- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03255759
Actionable Results: Bloodstream Infection Molecular Assay Evaluation
Assessment of the Use and Impact of a Molecular Identification Assay in the Diagnosis and Management of Bloodstream Infections at in Healthcare Settings in Princess Marina Hospital, Botswana
A number of rapid panel-based molecular assays for direct organism identification and resistance characterization in positive blood culture bottles are now commercially available. They have been shown to improve accuracy and decrease the time-to-result, allowing targeted treatment in hospitalized patients with bacteraemia, in high-income countries (HICs). However, these molecular assays are add-on tests performed in addition to conventional testing, increasing the complexity of diagnostic algorithms and costs of patient care. Conventional organism identification includes performing a Gram stain, biochemical identification and phenotypic drug susceptibility testing. The FilmArray Blood Culture Identification (BioFire, USA) is an example of a rapid panel-based molecular assay that combines nesting and multiplexing of PCR (nested multiplex PCR) to detect multiple pathogens simultaneously. There are limited data on how such tests impact patient management, health care costs and how they can better be incorporated into diagnostic algorithms.
The aim of this study is to assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will address the following questions:
- What impact can we project if additional diagnostic information were to be provided to clinicians in terms of patient outcomes, costs, and antibiotic use?
- What are the workflow constraints on returning diagnostic results to clinicians and/or antibiotic stewardship programs? Overall, the aim is to assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs and to assess health care providers' satisfaction with the assay.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gaborone, Botswana
- Princess Marina Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- For patients of Princess Marina Hospital: all participants who have a blood culture done as part of routine clinical care that is found to be positive through routine laboratory testing from Monday-Friday 8am-3pm (excluding holidays) will be eligible for inclusion in the study, regardless of age and co-morbidities.
- For the professionals making use of molecular testing: Attending physicians (paediatricians, internists, and physician trainees [residents, medical officers, interns]) caring for adults and children who are enrolled in the study, Microbiologists and microbiology technologists who have experience operating the BioFire FilmArray and/or traditional blood culture incubation systems at the laboratory.
Exclusion Criteria:
- For patients of Princess Marina Hospital: Individuals who have previously participated in the study by having a blood culture positive in the week prior will not be eligible to participate again within the 7-day time frame.
- For professionals making use of molecular testing: Individuals working with patients or laboratory samples at Princess Marina Hospital for less than one month will not be asked to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Molecular dx arm
Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
|
To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
|
No Intervention: Standard of care arm
Positive blood cultures are treated as per normal lab protocol (biochemical identification)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from blood collection to definitive treatment initiation (optimal treatment defined as time from blood culture collection to the initiation of a predetermined pathogen-specific antimicrobial therapy)
Time Frame: 1year
|
The judgment as to whether antimicrobial treatment was effective or optimal will be assessed by two members of the study team (infectious disease specialists and/or microbiologists) blinded to treatment group.
A third, blinded, party member will be available to adjudicate unresolved disagreements.
The Principal Investigators will not be involved in outcome classification.
|
1year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from blood collection to initiation of effective antimicrobial therapy (initiation of antimicrobials active against the identified causative pathogen)
Time Frame: 1year
|
The aim is to understand the reduction in time it takes clinical staff to act upon the result.
Faster treatment is associated with reduced mortality.
|
1year
|
Time from blood collection to pathogen identification
Time Frame: 1year
|
The hypothesis is that faster identification will lead to faster action.
|
1year
|
Proportion of patients with a confirmed diagnosis of bloodstream infection who are started on optimal antimicrobial therapy in the intervention compared to control arm.
Time Frame: 1year
|
This outcome will inform how the inclusion of a faster diagnosis can support antibiotic stewardship efforts.
|
1year
|
Frequency of discrepant results between molecular identification vs standard of care.
Time Frame: 1year
|
Current panels are design for common pathogens in the USA and Europe and given that this is the first evaluation in Africa it will advice on the suitability.
|
1year
|
Clinicians' satisfaction with the assay, predominantly in terms of time-to-result and actionable results.
Time Frame: 2month
|
To inform future projects and help guide implementation efforts.
|
2month
|
Laboratory professional satisfaction with the assay, predominantly in terms of ease of use and workflow.
Time Frame: 2month
|
To inform future projects and help guide implementation efforts.
|
2month
|
In-hospital mortality.
Time Frame: 1year
|
Faster treatment is associated with reduced mortaltity and as a secondary outcome we want to assess the difference between standard of care and diagnostic intervention.
|
1year
|
30-day mortality.
Time Frame: 1year
|
Faster treatment is associated with reduced mortaltity and as a secondary outcome we want to assess the difference between standard of care and diagnostic intervention.
|
1year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jeffrey Pernica, MD, FRCPC, McMaster University
- Principal Investigator: David Goldfarb, MD, FRCPC, University of British Columbia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08821/1/1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bloodstream Infection
-
Mayo ClinicTerminatedCatheter-related Bloodstream Infection (CRBSI) Nos | Bloodstream Infection Due to Central Venous Catheter | Bloodstream Infection Due to Hickman CatheterUnited States
-
Fudan UniversityShanghai Zhongshan Hospital; Huashan Hospital; Children's Hospital of Fudan University and other collaboratorsRecruitingQuality Improvement | Central Venous Catheter Associated Bloodstream Infection | CLABSI - Central Line Associated Bloodstream Infection | Central Venous Catheter Related Bloodstream Infection | Central Line Infection | CRBSI - Catheter Related Bloodstream Infection | Evidence-based Nursing PracticeChina
-
University of ZurichNot yet recruitingCentral Line-associated Bloodstream Infection (CLABSI) | Catheter-related Bloodstream Infection
-
Istanbul Medeniyet UniversityRecruitingCatheter-Related Infections | Central Venous Catheter Related Bloodstream Infection | Bloodstream Infection Due to Central Venous CatheterTurkey
-
The Cleveland ClinicJVS Products, Ltd.CompletedCatheter-related Bloodstream InfectionUnited States
-
University Hospital of Canary IslandsCompletedCatheter-related Bloodstream InfectionSpain
-
Boston Children's HospitalRecruitingLaboratory-confirmed Bloodstream Infection | Central Line-associated Bloodstream Infections | Mucosal Barrier InjuryUnited States
-
The University of QueenslandShionogiCompletedBloodstream InfectionsTaiwan, Thailand, Singapore, Australia, Malaysia, Turkey
-
University of MalayaTeleflexRecruitingCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
The University of QueenslandCompletedBloodstream InfectionsSingapore, Australia
Clinical Trials on Multiplex molecular diagnostic assay
-
Assistance Publique - Hôpitaux de ParisBiofireCompletedAcute Diarrhea | Acute Colitis of Presumed Infectious OriginFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingKidney Transplant; Complications | Diarrhoea;Acute | Diarrhea Infectious
-
DiaSorin Inc.Enrolling by invitation
-
IRCCS Policlinico S. MatteoCompleted
-
Meir Medical CenterCompleted
-
Karolinska InstitutetMbarara University of Science and Technology; Science for Life Laboratory; Epicentre... and other collaboratorsCompleted
-
Hospital Universitari de BellvitgeFundació La Marató de TV3; Department of Health, Generalitat de CatalunyaTerminatedCommunity-acquired PneumoniaSpain
-
Hoffmann-La RocheFoundation MedicineRecruitingMetastatic Lung Cancer | Metastatic Gastrointestinal CancerSpain, France, Italy, Germany, Netherlands
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
ENTvantage DxBeaufortTerminated